HIV/AIDS Clinical Trials

A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients

Condition: HIV Infection; HIV; Acquired Immunodeficiency Syndrome

NCT ID: NCT00903682

A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women

Condition: HIV; HIV Infections; Pregnancy

NCT ID: NCT00855335

TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents

Condition: HIV Infections; HIV-1

NCT ID: NCT00980538

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

Condition: HIV Infections; Acquired Immunodeficiency Syndrome

NCT ID: NCT00896051

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients

Condition: Human Immunodeficiency Virus (HIV) Infection

NCT ID: NCT01422330

TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients

Condition: HIV-Infections

NCT ID: NCT01090648

An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients

Condition: Human Immunodeficiency Virus (HIV)

NCT ID: NCT01615601

Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily

Condition: HIV-1 Infection; HIV Infections

NCT ID: NCT01121809

Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection

Condition: HIV Infections

NCT ID: NCT00959894

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses

Condition: HIV Infections

NCT ID: NCT00460382

Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study

Condition: Endothelial Function; Lipids; Insulin Resistance; Inflammation; HIV Infections

NCT ID: NCT00871234

TMC125-C223: TMC125 in HIV-1 Infected Subjects

Condition: HIV Infection

NCT ID: NCT00081978

TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 Trial

Condition: HIV Infection

NCT ID: NCT00111280

TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use

Condition: HIV Infection

NCT ID: NCT00225303

Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs

Condition: HIV Infection

NCT ID: NCT01543035

Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue

Condition: HIV/AIDS; HIV Infections

NCT ID: NCT00855088

Etravirine Plus 2 Analogs in HIV-infected Patients

Condition: HIV-1-infection

NCT ID: NCT01437241

A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).

Condition: HIV-1 Infection

NCT ID: NCT00534352

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

Condition: Human Immunodeficiency Virus Type 1

NCT ID: NCT00128830

A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

Condition: HIV-1

NCT ID: NCT00823979

Terminated

Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/HCV Negative Volunteers

Condition: Hepatitis C; HIV

NCT ID: NCT01427504

Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma

Condition: HIV

NCT ID: NCT01625169

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

Condition: HIV Infections

NCT ID: NCT01504841

Recruiting(En español)

The First Failure Study

Condition: HIV; HIV Infections

NCT ID: NCT01118871

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Condition: Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic

NCT ID: NCT00782301

Withdrawn

TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.

Condition: HIV; Pharmacokinetics

NCT ID: NCT00828815

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

Condition: HIV

NCT ID: NCT00254046

TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

Condition: HIV

NCT ID: NCT00255099

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

Condition: HIV-1

NCT ID: NCT00665847

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.

Condition: HIV-1

NCT ID: NCT00354627

Approved for marketing

TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients

Condition: Anti-Retroviral Agents; HIV-1

NCT ID: NCT00412646

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01199731

Terminated

Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression

Condition: HIV

NCT ID: NCT01034917

TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.

Condition: HIV; AIDS; Fungal Infection

NCT ID: NCT00740389

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut

Condition: HIV Infections

NCT ID: NCT00884793

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

Condition: HIV

NCT ID: NCT00460746

A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects

Condition: HIV Infections

NCT ID: NCT01045369

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

Condition: HIV-1

NCT ID: NCT00359021

TMC 125 Blood Levels Study

Condition: HIV Infections

NCT ID: NCT00531323

Sex, Aging and Antiretroviral Pharmacokinetics

Condition: HIV Infections

NCT ID: NCT00666055

Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

Condition: HIV Infections

NCT ID: NCT00977756

A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022

Condition: HIV-1

NCT ID: NCT01254656

Terminated

TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.

Condition: HIV

NCT ID: NCT00767117

TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.

Condition: Hepatitis C; HIV

NCT ID: NCT01336829

A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure

Condition: HIV-1 Infection

NCT ID: NCT01641367

Kaletra in Combination With Antiretroviral Agents

Condition: Human Immunodeficiency Virus

NCT ID: NCT01076179

A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence

Condition: Acquired Immune Deficiency Syndrome

NCT ID: NCT01741844

Active, not recruiting(En español)

Optimizing Treatment for Treatment-Experienced, HIV-infected People

Condition: HIV Infections

NCT ID: NCT00537394

DDI Study of Etravirine and GSK1265744

Condition: Healthy Subjects; Infection, Human Immunodeficiency Virus

NCT ID: NCT00920296

Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125

Condition: HIV

NCT ID: NCT00792324

INROADS, Abbreviated Title: Intelence aNd PRezista Once A Day Study

Condition: HIV

NCT ID: NCT01199939

Drug Interactions Between Echinacea Purpurea and Etravirine

Condition: HIV

NCT ID: NCT01347658

GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.

Condition: HIV Infections; Infection

NCT ID: NCT00381303

BRAVO: Background Regimen of Raltegravir on Virologic Outcome

Condition: HIV Infections

NCT ID: NCT00751530

Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure

Condition: HIV; AIDS; Lopinavir; Treatment Failure

NCT ID: NCT01189695

Drug Exposure Registry for GSK2248761, an Investigational NNRTI

Condition: Seizures; Infection, Human Immunodeficiency Virus

NCT ID: NCT01458132

Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)

Condition: Human Immunodeficiency Virus

NCT ID: NCT01814722

Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children

Condition: This Study is Designed to Collect Treatment Data of Thai Children on Third Line ARV Therapy.

NCT ID: NCT01225406

GSK1349572 Drug Interaction Study With Efavirenz

Condition: Infections, Human Immunodeficiency Virus and Herpesviridae; Healthy

NCT ID: NCT01098526

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

Condition: Kaposi's Sarcoma

NCT ID: NCT01276236

Enrolling by invitation

Clinical Trial of CNS-targeted HAART (CIT2)

Condition: HIV Infections

NCT ID: NCT00624195

Telaprevir Open-Label Study in Co-Infected Patients

Condition: Hepatitis C, Chronic

NCT ID: NCT01500616

Safety Study of Maraviroc's Effect on Human Osteoclasts

Condition: HIV Infections; AIDS

NCT ID: NCT01428986

Enrolling by invitation

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Condition: HIV Infections

NCT ID: NCT00042289

Recruiting(En español)

Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz

Condition: Sleep Disorders

NCT ID: NCT00792584